MGY825 / Novartis - LARVOL DELTA

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=41 | Terminated | Sponsor: Novartis Pharmaceuticals | N=140 ➔ 41 | Trial completion date: Jul 2027 ➔ Oct 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2027 ➔ Oct 2025; The trial was terminated due to a business decision and not as a result of any safety concerns

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KEAP1 • NFE2L2

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2026 ➔ Jul 2027 | Trial primary completion date: Aug 2026 ➔ Jul 2027

Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KEAP1 • NFE2L2

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KEAP1 • NFE2L2

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=1 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2025 ➔ Aug 2026 | Trial primary completion date: Feb 2025 ➔ Aug 2026

Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KEAP1 • NFE2L2

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=1 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=140 ➔ 1

Enrollment change • Enrollment closed • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KEAP1 • NFE2L2

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KEAP1 • NFE2L2